Poster Abstract Session:
185. Antiretroviral Treatment
Saturday, October 20, 2012: 12:30 PM-2:00 PM
Room: SDCC Poster Hall F-H

Topical Category: H. HIV/AIDS and Other Retroviruses

Tracks: HIV-STD-TB


Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (Quad) Demonstrates Comparable Efficacy and Favorable Tolerability to Efavirenz/Emtricitabine /Tenofovir DF in Patients with Adherence <95%
Edwin DeJesus, MD, FACP ; William Robbins, MD ; Fritz Bredeek, MD, PhD, FACP ; Peter Shalit, MD ; Kirsten White, PhD ; Hiu Liu, PhD ; Lauren Dau, PharmD ; Erin Quirk, MD ; David Piontkowsky, JD, MD

Analysis of EVG/COBI/FTC/TDF (Quad) Compared to EFV/FTC/TDF (ATR) by Race in Treatment Naive Patients
W. David Hardy, MD ; Peter Ruane, MD ; Kimberly Workowski, MD, FIDSA ; Martin Rhee, MD ; David Piontkowsky, JD, MD

Effects of Adherence and Baseline Viral Load (BL VL) on Virologic Response, with Further Safety Analyses, Among Women Compared to Men in the Phase III Week 96 ECHO and THRIVE Trials of Rilpivirine (RPV, TMC278) versus Efavirenz (EFV)
Sally Hodder, MD ; Claudia Martorell, MD, MPH, FACP ; Judith Feinberg, MD ; Princy N. Kumar, MD ; Sharon Walmsley, MD, FRCP ; Simon Vanveggel, MSc ; Laurence Rimsky, PhD ; Marita Stevens, MD

Lopinavir/Ritonavir Once Daily Monotherapy Pilot Study: The MONDAKAL Study
Harold Katner, MD ; Ritu Kumar, MD ; Cheryl Nylund, RN ; Shawn Jackson ; Sophia James, RN ; Emeka Obiekwe ; Kimberly Hollar, PharmD
  • Katner 10152012.pdf (2.2 MB)

  • Brief Interruption of HIV Antiretroviral Therapy in Patients with Preserved CD4 Count and Virologic Suppression is Safe and Well Tolerated
    Meghan Rothenberger, MD ; Ashley Haase, MD ; Alexander Khoruts, MD ; Gregory Beilman, MD ; Jeffrey Chipman, MD ; Ann Thorkelson, RN ; Cavan Reilly, PhD ; Netanya Sandler, MD ; Daniel Douek, MD, PhD ; Mario Stevenson, PhD ; Timothy Schacker, MD

    CME Credits:

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 17th with the exception of research findings presented at the IDWeek press conferences.